These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
123 related articles for article (PubMed ID: 38815448)
1. Preclinical studies and absorbed dose estimation of [ Zolghadri S; Mohammadpour-Ghazi F; Yousefnia H Appl Radiat Isot; 2024 Aug; 210():111379. PubMed ID: 38815448 [TBL] [Abstract][Full Text] [Related]
2. Development of a Specifically Labeled Zheng M; Liu Q; Zhang H; Wang Y; Zhang K; Mu H; Fu F; Zhang X; Wang Y; Miao L Mol Pharm; 2024 Oct; 21(10):5205-5216. PubMed ID: 39322604 [TBL] [Abstract][Full Text] [Related]
4. Biodistribution and pharmacokinetics of [ García-Varela L; Codesido J; Perez-Pedrosa A; Muñoz-González M; Ramos-Docampo E; Rey-Bretal D; García-Otero X; Gómez-Lado N; Turrero A; Beiroa D; Rodríguez-Perez AI; Vidal A; Fernández-Ferreiro A; Pubul V; Aguiar P Int J Pharm; 2024 Mar; 652():123795. PubMed ID: 38224761 [TBL] [Abstract][Full Text] [Related]
5. A comparison of DFO and DFO* conjugated to trastuzumab-DM1 for complexing Cho H; Al-Saden N; Lam H; Möbus J; Reilly RM; Winnik MA Nucl Med Biol; 2020; 84-85():11-19. PubMed ID: 31931305 [TBL] [Abstract][Full Text] [Related]
6. Preclinical ImmunoPET Imaging Using a Zr-89-Labeled Anti-CD146 Monoclonal Antibody for Diagnosis of Melanoma. Guo X; Hu M; Zhang Q; Liu J; Shi J; Tang Y; Liu S; Guo J; Kong Y; Zhu H; Yang Z Mol Pharm; 2024 Sep; 21(9):4490-4497. PubMed ID: 39077827 [TBL] [Abstract][Full Text] [Related]
7. Zirconium- 89 Labeled Antibody K1-70 for PET Imaging of Thyroid-stimulating Hormone Receptor Expression in Thyroid Cancer. Parent EE; Gleba JJ; Knight JA; Kenderian SJ; Copland JA; Cai H Mol Imaging Biol; 2024 Oct; 26(5):847-857. PubMed ID: 39174789 [TBL] [Abstract][Full Text] [Related]
8. Measurement of tumor VEGF-A levels with 89Zr-bevacizumab PET as an early biomarker for the antiangiogenic effect of everolimus treatment in an ovarian cancer xenograft model. van der Bilt AR; Terwisscha van Scheltinga AG; Timmer-Bosscha H; Schröder CP; Pot L; Kosterink JG; van der Zee AG; Lub-de Hooge MN; de Jong S; de Vries EG; Reyners AK Clin Cancer Res; 2012 Nov; 18(22):6306-14. PubMed ID: 23014526 [TBL] [Abstract][Full Text] [Related]
11. Comparison of the octadentate bifunctional chelator DFO*-pPhe-NCS and the clinically used hexadentate bifunctional chelator DFO-pPhe-NCS for Vugts DJ; Klaver C; Sewing C; Poot AJ; Adamzek K; Huegli S; Mari C; Visser GWM; Valverde IE; Gasser G; Mindt TL; van Dongen GAMS Eur J Nucl Med Mol Imaging; 2017 Feb; 44(2):286-295. PubMed ID: 27573793 [TBL] [Abstract][Full Text] [Related]
12. A radiopharmaceutical [ Tang Y; Hu Y; Liu W; Chen L; Zhao Y; Ma H; Yang J; Yang Y; Liao J; Cai J; Chen Y; Liu N Nucl Med Biol; 2019 Mar; 70():23-31. PubMed ID: 30826708 [TBL] [Abstract][Full Text] [Related]
16. A generic Li N; Yu Z; Pham TT; Blower PJ; Yan R Int J Nanomedicine; 2017; 12():3281-3294. PubMed ID: 28458546 [TBL] [Abstract][Full Text] [Related]
17. What is the Best Radionuclide for Immuno-PET of Multiple Myeloma? A Comparison Study Between Bailly C; Gouard S; Guérard F; Chalopin B; Carlier T; Faivre-Chauvet A; Remaud-Le Saëc P; Bourgeois M; Chouin N; Rbah-Vidal L; Tripier R; Haddad F; Kraeber-Bodéré F; Bodet-Milin C; Chérel M Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31137758 [TBL] [Abstract][Full Text] [Related]
19. DFO-Km: A Modular Chelator as a New Chemical Tool for the Construction of Zirconium-89-Based Radiopharmaceuticals. Salih AK; Dominguez Garcia M; Raheem SJ; Ahiahonu WK; Price EW Inorg Chem; 2023 Dec; 62(50):20806-20819. PubMed ID: 37751491 [TBL] [Abstract][Full Text] [Related]
20. Molecular Drug Imaging: Jansen MH; Veldhuijzen van Zanten SEM; van Vuurden DG; Huisman MC; Vugts DJ; Hoekstra OS; van Dongen GA; Kaspers GL J Nucl Med; 2017 May; 58(5):711-716. PubMed ID: 27765855 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]